(CN) – The Federal Trade Commission wants to block CSL Ltd.’s proposed $3.1 billion buyout of Talecris Biotherapeutics, Australia-based CSL is the world’s second-largest supplier of therapies for rare immune-deficiency diseases, coagulation disorders, and respiratory diseases. New York-based Talecris is the third-largest producer of plasma-derivative protein therapies.
CSL seeks to acquire all outstanding voting shares held by Talecris Biotherapeutics Holdings Corp.
Talecris began U.S. operations when it acquired Bayer’s worldwide plasma business in 2005.
Both CSL and Talecris own plasma collection centers and manufacturing facilities in the U.S.
The FTC claims CSL’s acquisition of Talecris would reduce competition among plasma pharmaceutical companies in the United States, allowing CSL to dominate already too-narrow markets.
The FTC seeks a federal injunction in Washington D.C.